Nasdaq: Change Healthcare Launches InterQual® 2022, Delivering the Latest Evidence-Based Criteria and Technology to Optimize Clinical Decision Support
InterQual solutions provide health care providers and health plans nationwide with evidence-based, independently peer-reviewed criteria and workflow enhancements to streamline utilization management ...
Change Healthcare Launches InterQual® 2022, Delivering the Latest Evidence-Based Criteria and Technology to Optimize Clinical Decision Support
NEWTON, Mass.--(BUSINESS WIRE)--Today McKesson Health Solutions (MHS) announced that the Centers for Medicare & Medicaid Services (CMS) will continue their long-term use of InterQual ® Criteria for ...
While UnitedHealthcare will provide organizations with criteria to make status decisions for patients, it will not provide hospitals with the complete set of InterQual criteria. Q: As of May 1, ...
NEWTON, Mass.--(BUSINESS WIRE)--McKesson Health Solutions (MHS) has announced that InterQual ® Criteria, the standard for evidence-based clinical decision support, is now accessible on demand through ...
Replaces competing solution, points to InterQual Connect’s unique authorization and connectivity capabilities as decisive factor in licensing 12 InterQual Criteria sets and more NEWTON, ...
NEWTON, Mass.--(BUSINESS WIRE)--Change Healthcare today unveiled InterQual ® 2019, the latest edition of the company's flagship clinical decision support solution. The new release builds on Change ...
YouTube’s mission is to give everyone a voice and show them the world. Learn about our brand, community, careers and more.
The SOFT Estrogen Substudy (SOFT-EST) was a prospective substudy of SOFT, which evaluated estradiol (E2) levels to determine if patients on exemestane and triptorelin experienced suboptimal ovarian function suppression.
When combined with ovarian function suppression (OFS), AIs like exemestane become highly effective at reducing estrogen levels throughout the body, significantly improving outcomes for hormone receptor-positive premenopausal breast cancer, as demonstrated by the SOFT and TEXT trials.